Studieoverzicht

 
 
 
  2022-05 EMBER-4       Submitted (METC)       Adjuvant       HER2- HR+       Both pre- and postmenopausal  
  2022-01 DIRECT-2       Open       Neoadjuvant       HER2- HR+       Both pre- and postmenopausal  
  2021-04 TROPION-Breast01       Active, not recruiting       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2021-03 EMBER-3       Open       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2021-01 SEQUEL-Breast       Open       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2020-02 AMEERA-5       Active, not recruiting       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2019-01 TIBET       Open       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2017-04 BYLieve       Follow up       Advanced/metastatic       HER2- HR+       Not applicable  
  2017-03 SONIA       Active, not recruiting       Advanced/metastatic       HER2- HR+       Not applicable  
  2017-01 NEOLBC       Follow up       Neoadjuvant       HER2- HR+       Postmenopausal  
  2016-02 PALLAS       Follow up       Adjuvant       HER2- HR+       Both pre- and postmenopausal  
  2016-01 TOP-1       Follow up       Data registration       HER2- HR+       Postmenopausal  
  2015-02 MonaLEEsa-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2015-01 Monarch-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2014-01 MONALEESA-2       Closed       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2013-06 Biomarker Study Everolimus       Closed       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2013-05 BELLE-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2012-01 BALLET       Closed       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2011-01 Abiraterone       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2009-05 BOLERO 2       Closed       Advanced/metastatic       HER2- HR+       Postmenopausal